US FDA New Drug Application Approval of Ohtuvayre™ (ensifentrine) for the Maintenance Treatment of COPD
SHANGHAI, June 27, 2024 /PRNewswire/ -- Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in...
Amsino Medical Group announces transformational investment from Novo Tellus
POMONA, Calif., June 27, 2024 /PRNewswire/ -- Amsino Medical Group ("Amsino"), a global provider of medical consumable devices, is pleased to announce the closing of a substantial investment by Novo Tellus, a leading investment firm specialising in long-term investments in the global supply chain. Amsino Medical Group Company announces transformational investment from...
NSW Government extends it support for community heart health initiatives
SYDNEY, June 27, 2024 /PRNewswire/ -- The Heartbeat of Football Foundation (the Foundation) is excited to announce an additional grant of $150,000 from the NSW Government to deliver more community sport focused heart health initiatives across regional NSW sporting grounds until 2026. The "#HeartHealthMatters - Community + Sport" project is about helping build stronger, healthier, happier, and safer...
Easy and Fast “Cat Urine Test Kit” for Early Detection of Kidney Disease, Gallstones, and Cystitis
BANGKOK, June 27, 2024 /PRNewswire/ -- Researchers from Chula Faculty of Science invented an easy-to-use "Cat Urine Test Kit" to screen for the risk of kidney disease, gallstones, and cystitis in cats. The test kit provides fast and accurate results, so cats can be treated promptly. All cat lovers want to see...
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 27, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announces that it has resubmitted the Biologics License Application (BLA) of batoclimab (HBM9161) to...
Suvoda Expands its Clinical Trial Offering with the Introduction of ePatient
With the focus on improving patient experience and reducing burden on sites PHILADELPHIA, June 27, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases, announced the early adopter launch of its ePatient product....
Nutiani report reveals age-agnostic interest and proactive consumers in healthy ageing space
AUCKLAND, New Zealand, June 27, 2024 /PRNewswire/ -- Nutiani's latest Consumer Health and Nutrition Index, conducted in collaboration with Ipsos, indicates a strong and growing consumer focus on ageing healthily. This is underpinned by a strong preventive mindset (88%) and a firm awareness on the role of nutrition in health management (82%) going into one's golden years. Against the...
The Future of Telehealth Relies on Seamless UC&C Monitoring
IR launches a healthcare bundle to meet the demands of proactive communication monitoring in healthcare organizations. SYDNEY, June 26, 2024 /PRNewswire/ -- IR (ASX:IRI), a leading provider of global performance management and analytics for Unified Communications and Collaboration (UC&C), has announced a healthcare bundle to maintain fault-free communication, in...
HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002
HANGZHOU, China, June 26, 2024 /PRNewswire/ -- HUADONG MEDICINE, through its wholly-owned subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO. LTD (Zhongmei HuaDong), has recently announced positive results from Phase I clinical trials of its innovative oral small molecule GLP-1 receptor agonist HDM1002 in China. The Phase Ia trial of HDM1002 in China was a randomized, double-blind, placebo-controlled study evaluating the...
TurtleTree Announces Strategic Partnership with Strive, a Sustainable Nutrition Company; Expands Consumer Product Offerings with LF+™ for Adult and Sports Nutrition
Strive and TurtleTree to Collaborate on a Immunity Support Beverage for Adults and a Protein Powder to be Made Available to the Public Q1 2025 SACRAMENTO, Calif. and SINGAPORE, June 26, 2024 /PRNewswire/ -- TurtleTree, a pioneer in sustainable nutrition, today announces a multi-year strategic partnership with Strive, a nutrition company focused on...
